Pfizer Inc. / 3SBio Inc.

Non-Small Cell Lung Cancer (NSCLC)

234K US cases/yr · $32.0B Global NSCLC therapeutics market 2030E · ~125,000 Annual US lung cancer deaths

Disease Overview

Non-small cell lung cancer accounts for approximately 85% of all lung cancer diagnoses and remains the leading cause of cancer death in the United States, with roughly 234,000 new cases and 125,000 deaths annually. Disease is typically diagnosed at advanced stage, with adenocarcinoma the dominant histology. Molecular stratification for EGFR, ALK, ROS1, BRAF, KRAS G12C, HER2, MET, RET, NTRK and PD-L1 has reshaped first-line decisions; in biomarker-negative patients, checkpoint inhibitors combined with platinum-doublet chemotherapy are the standard of care. First-line pembrolizumab-based regimens established by KEYNOTE-189 and KEYNOTE-407 deliver median overall survival of 22-23 months but most patients eventually progress, and PD-L1-low patients benefit less. Clinical interest has shifted toward strategies that combine PD-(L)1 blockade with anti-angiogenic signaling, motivated by Ivonescimab's Phase 3 HARMONi-2 readout (Summit Therapeutics/Akeso) demonstrating superiority to pembrolizumab monotherapy in first-line PD-L1-positive NSCLC in a head-to-head Chinese trial. PD-1/VEGF bispecifics are now positioned as the central pharmacologic innovation of the 2025-2030 cycle, with broad development across NSCLC, colorectal and gynecologic tumors.

Competitive Landscape

The first-line NSCLC market is dominated by Keytruda (pembrolizumab, Merck) across monotherapy (PD-L1 TPS >=50%) and combination (KEYNOTE-189/407) settings, with Tecentriq (atezolizumab, Roche), Opdivo + Yervoy (nivolumab + ipilimumab, BMS), Libtayo (cemiplimab, Regeneron) and Imfinzi (durvalumab, AstraZeneca) competing in selected subsets. Anti-angiogenic Avastin (bevacizumab, Roche, anti-VEGF-A) is used in combination regimens. The emerging and most disruptive class is PD-(L)1/VEGF bispecific antibodies led by ivonescimab (Summit Therapeutics/Akeso, AK112, PD-1/VEGF-A), which demonstrated superiority to pembrolizumab in the Chinese Phase 3 HARMONi-2 trial in 2024 and is advancing through global HARMONi and HARMONi-3 studies. SSGJ-707 (Pfizer/3SBio, PD-1/VEGF bispecific) is now Pfizer's direct entry into this class via the May 2025 license deal. Other PD-1/VEGF or PD-L1/VEGF bispecifics in development include PM8002 (Biotheus/BioNTech), HB0025 (Huabo Biopharm), LY3434172 (Eli Lilly) and multiple Chinese programs. Target classes shaping later lines include KRAS G12C inhibitors (Lumakras/sotorasib, Krazati/adagrasib), TROP2 ADCs (datopotamab deruxtecan, sacituzumab govitecan), HER3 ADCs (patritumab deruxtecan) and EGFR-exon20 agents (amivantamab, Rybrevant).

Gynecologic Cancers

Competitive Landscape

Gynecologic cancers (ovarian, endometrial, cervical) are a diverse MOA landscape where SSGJ-707 (PD-1/VEGF bispecific) must win against class-leading combinations. Anti-PD-1/PD-L1 monotherapy and combos: pembrolizumab (Keytruda, Merck, ~$25B 2023) is approved in cervical cancer, MSI-H endometrial (with lenvatinib), and dMMR tumor-agnostic; dostarlimab (Jemperli, GSK) is approved for primary advanced/recurrent endometrial cancer in combination with chemo (RUBY trial, 2023). Anti-VEGF: bevacizumab (Avastin, Roche; ~$5B pre-biosimilar, now generics) is approved in ovarian, cervical, and platinum-sensitive recurrent ovarian. PARP inhibitors: olaparib (Lynparza, AZ/Merck, ~$2.6B 2023), niraparib (Zejula, GSK), and rucaparib (Rubraca, Pharma&) dominate ovarian maintenance across BRCA-mutant and HRD-positive populations. ADCs: mirvetuximab soravtansine (Elahere, AbbVie/ImmunoGen; FRalpha+ platinum-resistant ovarian, accelerated approval November 2022, full approval March 2024) and tisotumab vedotin (Tivdak, Genmab/Pfizer; cervical, approved September 2021, full approval April 2024). TKIs: lenvatinib (Lenvima, Eisai/Merck) in combo with pembrolizumab for endometrial. Direct PD-1/VEGF bispecific rival: ivonescimab (Summit/Akeso; Phase 3 HARMONi programs across multiple tumors). For Pfizer, SSGJ-707 must deliver a bevacizumab-sparing or Keytruda-better outcome to displace entrenched combination regimens; the most addressable whitespace is platinum-resistant ovarian cancer post-mirvetuximab and PD-L1-low cervical where Keytruda's benefit is attenuated.

Metastatic Colorectal Cancer

Competitive Landscape

Metastatic colorectal cancer (mCRC) is an established market defined by biomarker-stratified regimens, and SSGJ-707 (PD-1/VEGF bispecific) with chemotherapy must differentiate in a crowded space. Anti-VEGF biologics: bevacizumab (Avastin, Roche; biosimilars Mvasi, Zirabev, Vegzelma since 2017) plus FOLFOX/FOLFIRI is the 1L standard; ramucirumab (Cyramza, Lilly) and ziv-aflibercept (Zaltrap, Regeneron/Sanofi) serve second-line post-bevacizumab. Anti-EGFR: cetuximab (Erbitux, Lilly/Merck KGaA) and panitumumab (Vectibix, Amgen) for RAS wild-type left-sided tumors. Anti-PD-1: pembrolizumab (Keytruda, Merck, ~$25B 2023) is 1L standard for MSI-H/dMMR mCRC (KEYNOTE-177); nivolumab+ipilimumab (Opdivo+Yervoy, BMS) and nivolumab monotherapy also approved for MSI-H. BRAF-targeted: encorafenib+cetuximab (Braftovi+Erbitux, Pfizer) for BRAF V600E post-1L. HER2-targeted: tucatinib+trastuzumab (Tukysa, Pfizer) and trastuzumab deruxtecan (Enhertu, AZ/Daiichi) for HER2+ mCRC. KRAS G12C: sotorasib (Lumakras, Amgen) and adagrasib (Krazati, BMS/Mirati; mCRC accelerated approval June 2024 in combo with cetuximab). Direct PD-1/VEGF bispecific rival: ivonescimab (Summit/Akeso) Phase 3 HARMONi-6 in mCRC. For Pfizer, SSGJ-707+chemo's threat is primarily to bevacizumab+chemo in MSS populations; the commercial opportunity depends on demonstrating PFS improvement over a biosimilar-priced bev-chemo backbone and capturing the large MSS segment that Keytruda cannot address.

Non-Small Cell Lung Cancer (NSCLC)

Competitive Landscape

NSCLC is the most competitive oncology market and SSGJ-707 (PF-08634404, PD-1/VEGF bispecific) enters against a crowded immuno-oncology backbone. Anti-PD-1/PD-L1 monotherapy and combos: pembrolizumab (Keytruda, Merck, ~$25B 2023; leading 1L NSCLC) across KEYNOTE-024, -189, -407; nivolumab+ipilimumab+chemo (Opdivo+Yervoy, BMS); atezolizumab (Tecentriq, Roche); durvalumab (Imfinzi, AstraZeneca); cemiplimab (Libtayo, Regeneron/Sanofi); and tislelizumab (Tevimbra, BeiGene). Anti-VEGF: bevacizumab (Avastin, Roche; biosimilars) plus chemo and ramucirumab (Cyramza, Lilly) in combo regimens with erlotinib for EGFR-mutant 1L. PD-1/VEGF bispecific (direct class): ivonescimab (Akeso/Summit) demonstrated PFS superiority over pembrolizumab in PD-L1+ NSCLC in HARMONi-2 (China, 2024 WCLC presentation), representing SSGJ-707's closest rival; Summit is running HARMONi-3 in 1L squamous NSCLC ex-China. ADCs: trastuzumab deruxtecan (Enhertu, AZ/Daiichi) for HER2-mutant NSCLC; datopotamab deruxtecan (Datroway, AZ/Daiichi) accelerated approval January 2025 in EGFR-mutant; patritumab deruxtecan (Merck) in HER3+ NSCLC pending. Targeted therapies: osimertinib (Tagrisso, AZ, ~$5.8B 2023), sotorasib (Lumakras, Amgen), adagrasib (Krazati, BMS/Mirati), and ALK/ROS1/MET/RET TKIs. For Pfizer, SSGJ-707's commercial threat comes primarily from Keytruda entrenchment and ivonescimab's first-mover PD-1/VEGF position; differentiation requires a PD-L1-agnostic superiority signal.